In this study, exosomes used to encapsulate curcumin (Exo-cur) or a Stat3 inhibitor, i.e., JSI124, (Exo-JSI124) were delivered non-invasively to microglila cells via an intranasal route. The results generated from three inflammation mediated disease models, i.e., a LPS induced brain inflammation model, experimental autoimmune encephalitis and a GL26 brain tumor model, showed that mice treated intranasally with Exo-cur or Exo-JSI124 are protected from LPS induced brain inflammation, the progression of MOG peptide induced EAE, and had significantly delayed brain tumor growth in the GL26 tumor model. Intranasal administration of Exo-cur or Exo-JSI124 led to rapid delivery of exosome encapsulated drug to the brain that was selectively taken up by microglial cells, and subsequently induced apoptosis of microglial cells. Our results demonstrate that this strategy may provide a non-invasive and novel therapeutic approach for treating brain inflammatory related diseases.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4831. doi:1538-7445.AM2012-4831